Pfizer Inc. $PFE is Hourglass Capital LLC's 6th Largest Position

Key Points

• Hourglass Capital LLC has increased its stake in Pfizer Inc. by 9% in Q2, making Pfizer its 6th largest position, valued at $10.58 million.
• Pfizer recently reported earnings of $0.78 per share, surpassing estimates and showing a 10.3% increase in revenue year-over-year, amounting to $14.65 billion.
• The company has announced a quarterly dividend of $0.43 per share, yielding 7.1%, with an ex-dividend date of November 7th.

Hourglass Capital LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 436,440 shares of the biopharmaceutical company's stock after buying an additional 35,900 shares during the quarter. Pfizer accounts for 2.6% of Hourglass Capital LLC's investment portfolio, making the stock its 6th largest position. Hourglass Capital LLC's holdings in Pfizer were worth $10,579,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the first quarter worth approximately $27,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter worth approximately $28,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth approximately $28,000. WPG Advisers LLC purchased a new stake in shares of Pfizer during the first quarter worth approximately $35,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer in the 1st quarter valued at $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock opened at $24.39 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82. The firm has a market capitalization of $138.69 billion, a P/E ratio of 12.98, a P/E/G ratio of 0.81 and a beta of 0.55. The business's 50-day moving average is $24.89 and its two-hundred day moving average is $24.13.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the company earned $0.60 EPS. The business's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer's payout ratio is 91.49%.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Morgan Stanley lowered their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a report on Friday, October 10th. Finally, UBS Group reiterated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of "Hold" and an average price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.